SynthesisInflammatory bowel diseases2026

Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis.

David T Rubin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.